BioSpace News Archive

Edwards Lifesciences Corporation announced the Edwards PASCAL transcatheter valve repair system has received CE Mark for the treatment of patients with mitral regurgitation.

Merck announced that the pivotal Phase 3 KEYNOTE-240 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy, did not meet its co-primary endpoints of overall survival and progression-free survival compared with placebo plus best supportive care.

Medical and Value Hearing Health Performance Drive Record Quarterly Revenue; Company Provides Guidance for 2019

Kirkbride Center is one of the largest Medication Assisted Treatment programs in Philadelphia.

Synthetic Biologics, Inc., a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial results for the year ended December 31, 2018 on Wednesday, February 27, 2019, and will host a conference call the same day at 4:30 p.m. EST.

Brave Like Gabe Fund launched at Memorial Sloan Kettering Cancer Center

SQI Diagnostics Inc., announced that it plans to release its financial and operational results for the three months ended December 31, 2018 at 8:00 a.m. ET Thursday, February 28, 2019.

Dr. Ian Smith Will Keynote The Conference To Address The Social Determinants For Men’s Primary Healthcare

Innovative Partnership Will Transform Transportation, Connectivity and Safety Throughout The Nation’s Second Largest Urban Medical District

In the news release, Theravance Biopharma to Report Fourth Quarter and Full Year 2018 Financial Results on February 26, issued 19-Feb-2019 by Theravance Biopharma, Inc.